{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "http://www.nerxbiosciences.com/#organization",
      "name": "NĒRx BioSciences Inc.",
      "url": "http://www.nerxbiosciences.com/",
      "description": "| info@nerxbiosciences.com X Instagram X Instagram Home About Us Research & Development Pipeline Overview NĒRx-329 NĒRx-3392 Additional Targets News Publications Grants Contact Us FCOI Select Page Innovation Uncompromised. A New Generation of Targeted Therapeutics for the Treatment of Cancer Welcome to NĒRx Biosciences, a pre-clinical stage biotechnology company developing novel anticancer therapeutics targeting DNA damage response (DDR) and DNA repair. NĒRx Biosciences has developed a novel strategy to realize the full therapeutic promise of the DDR, by targeting the proteins that detect DNA damage (DDR sensors), as opposed to proteins that react to the sensors (DNA kinases), to initiate DN"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/nerx-biosciences-inc#asg",
      "name": "NĒRx BioSciences Inc. ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/nerx-biosciences-inc",
      "isPartOf": {
        "@id": "http://www.nerxbiosciences.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}